CA3070717A1 - Inhibitors of plasma kallikrein and uses thereof - Google Patents

Inhibitors of plasma kallikrein and uses thereof Download PDF

Info

Publication number
CA3070717A1
CA3070717A1 CA3070717A CA3070717A CA3070717A1 CA 3070717 A1 CA3070717 A1 CA 3070717A1 CA 3070717 A CA3070717 A CA 3070717A CA 3070717 A CA3070717 A CA 3070717A CA 3070717 A1 CA3070717 A1 CA 3070717A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
amino
thiazole
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070717A
Other languages
English (en)
French (fr)
Inventor
Jeremy Travins
Thomas Miller
Nikolaos PAPAIOANNOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA3070717A1 publication Critical patent/CA3070717A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3070717A 2017-08-04 2018-08-03 Inhibitors of plasma kallikrein and uses thereof Pending CA3070717A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541403P 2017-08-04 2017-08-04
US62/541,403 2017-08-04
PCT/US2018/045183 WO2019028362A1 (en) 2017-08-04 2018-08-03 INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3070717A1 true CA3070717A1 (en) 2019-02-07

Family

ID=63209746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070717A Pending CA3070717A1 (en) 2017-08-04 2018-08-03 Inhibitors of plasma kallikrein and uses thereof

Country Status (6)

Country Link
US (3) US11168083B2 (enExample)
EP (2) EP3661922B1 (enExample)
JP (2) JP7210540B2 (enExample)
AU (3) AU2018311976B2 (enExample)
CA (1) CA3070717A1 (enExample)
WO (1) WO2019028362A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168083B2 (en) 2017-08-04 2021-11-09 Takeda Pharmaceutical Company Limited Inhibitors of Plasma Kallikrein and uses thereof
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
PT4031547T (pt) * 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
CA3167336A1 (en) * 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
CN116063215A (zh) * 2023-02-23 2023-05-05 南京安淮创新药物研究院有限公司 一种4-氨基-l-脯氨酸的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004792B1 (ru) 1998-06-30 2004-08-26 Пфайзер Продактс Инк. Непептидные ингибиторы vla-4-зависимого клеточного связывания, полезные в лечении воспалительных, аутоиммунных и респираторных заболеваний
CA2634743C (en) * 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
BR112014015582A8 (pt) * 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
SG11201706411YA (en) 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
CN107614532A (zh) * 2015-03-30 2018-01-19 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其预防遗传性血管性水肿发作的用途
WO2017001936A2 (en) * 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR102696432B1 (ko) 2015-10-01 2024-08-16 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US11168083B2 (en) 2017-08-04 2021-11-09 Takeda Pharmaceutical Company Limited Inhibitors of Plasma Kallikrein and uses thereof
WO2019178129A1 (en) * 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
PT4031547T (pt) * 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021055589A1 (en) * 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
DK4136091T3 (da) * 2020-04-17 2025-08-18 Takeda Pharmaceuticals Co Former og sammensætninger af plasmakallikreinhæmmere

Also Published As

Publication number Publication date
JP2023040213A (ja) 2023-03-22
AU2018311976A1 (en) 2020-02-06
US20240199602A1 (en) 2024-06-20
JP2020529998A (ja) 2020-10-15
EP4494698A2 (en) 2025-01-22
JP7210540B2 (ja) 2023-01-23
EP4494698A3 (en) 2025-04-23
AU2023200156B2 (en) 2025-04-24
AU2025204840A1 (en) 2025-07-17
AU2018311976B2 (en) 2022-10-13
EP3661922A1 (en) 2020-06-10
AU2023200156A1 (en) 2023-02-09
US11905285B2 (en) 2024-02-20
JP7427812B2 (ja) 2024-02-05
US20200239463A1 (en) 2020-07-30
EP3661922B1 (en) 2024-10-23
WO2019028362A1 (en) 2019-02-07
US20220056028A1 (en) 2022-02-24
US11168083B2 (en) 2021-11-09
JP2024045291A (ja) 2024-04-02

Similar Documents

Publication Publication Date Title
US11905285B2 (en) Inhibitors of plasma kallikrein and uses thereof
EP3544970B1 (en) Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
US20160046661A1 (en) Ras inhibitors and uses thereof
WO2018085247A1 (en) Compounds for malt1 degradation
EP3876939A1 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US20220395509A1 (en) A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
WO2018165385A1 (en) Inhibitors of malt1 and uses thereof
US11603349B2 (en) Anti-fibrotic compounds
JP7785108B2 (ja) 血漿カリクレインの阻害剤およびその使用
CA3218510A1 (en) Small molecule modulators of glucocerebrosidase activity and uses thereof
HK40123072A (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252A (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252B (en) Inhibitors of plasma kallikrein and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

EEER Examination request

Effective date: 20220927

EEER Examination request

Effective date: 20220927